ODTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Odyssey Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$18.10+0.93 (+5.42%)

Close on Oct 19, 2026

Market cap: $548.01M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q2 FY2026 Ended Jun 30, 2026	Aug 4, 2026	Before market open	–	–	–
Q1 FY2026 Ended Mar 31, 2026	Jun 17, 2026	During market hours	–	–	–

Press releases

Announcements Odyssey Therapeutics filed with the SEC

Sep 8, 2026, 7:10 PM ET
Oral RIPK2 Scaffolding Inhibitor: OD-001 Addressing a Root Cause of Inflammation in IBD Using a Novel Mechanism of Action Proof-of-Concept Achieved in Ulcerative Colitis Program Inception to Phase 2 Proof-of-Concept: 4.5 Years
Regulation FD disclosure · EX-99.1 to Form 8-K
Aug 4, 2026, 7:00 AM ET
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Jun 23, 2026, 8:45 AM ET
Oral RIPK2 Scaffolding Inhibitor: OD-001 Addressing a Root Cause of Inflammation in IBD Using a Novel Mechanism of Action Proof-of-Concept Achieved in Ulcerative Colitis Program Inception to Phase 2 Proof-of-Concept: 4.5 Years
Regulation FD disclosure · EX-99.1 to Form 8-K
Jun 17, 2026, 4:45 PM ET
Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K